HYPICNCT05961202
The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
Notable Eligibility criteria expanded, about 130 wordsv3 Show 7 more changesShow less
- Primary endpoint revised
- Primary completion date changed from estimate of Jun 1, 2024 to Sep 1, 2024
- Study completion date: Jun 1, 2025 to Nov 1, 2025
- Start date: Jan 1, 2022 to Nov 1, 2021
- Secondary endpoints: 3 to 6
- Publications: 3 to 4
- Study description expanded, about 3 words
- Minor Primary completion date: Jan 1, 2024 to Jun 1, 2024v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Composite cardiovascular outcome
Timeframe: 3 years
Secondary (6)
The increase and dynamic changes of LVEF (%)
The increase and dynamic changes of LVIDd (mm)
The decrease and dynamic changes of hs-cTnI (pg/mL)
The decrease and dynamic changes of NT-proBNP (pg/mL)
The decrease and dynamic changes of hs-CRP (mg/L)
Show 1 moreShow less
The decrease and dynamic changes of ESR (mm/H)
Arms and interventions
HCQ groupExperimental
Hydroxychloroquine 200mg qd and Prednisolone 20mg qd for 12 months
Non-HCQ groupActive comparator
Prednisolone 20mg qd for 12 months
Drugs: Hydroxychloroquine, Prednisolone
Sites
1 site in 1 country
- Tongji HospitalWuhan, Hubei, China